Xilio Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Xilio Therapeutics has a total shareholder equity of $25.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $82.6M and $56.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$33.98m |
| Equity | US$25.77m |
| Total liabilities | US$56.84m |
| Total assets | US$82.61m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: XLO's short term assets ($69.2M) exceed its short term liabilities ($31.6M).
Long Term Liabilities: XLO's short term assets ($69.2M) exceed its long term liabilities ($25.3M).
Debt to Equity History and Analysis
Debt Level: XLO is debt free.
Reducing Debt: XLO had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XLO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: XLO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.2% each year